Brokerages Set Evelo Biosciences Inc (NASDAQ:EVLO) PT at $21.50

Evelo Biosciences Inc (NASDAQ:EVLO) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $21.50.

A number of analysts have recently commented on the company. Zacks Investment Research downgraded Evelo Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, November 8th. Chardan Capital reissued a “neutral” rating on shares of Evelo Biosciences in a research note on Thursday, September 19th.

Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC raised its position in shares of Evelo Biosciences by 0.6% during the first quarter. FMR LLC now owns 3,325,107 shares of the company’s stock worth $26,601,000 after purchasing an additional 19,100 shares during the period. BlackRock Inc. grew its holdings in shares of Evelo Biosciences by 1.3% during the second quarter. BlackRock Inc. now owns 654,753 shares of the company’s stock valued at $5,879,000 after buying an additional 8,520 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Evelo Biosciences by 0.9% during the second quarter. Vanguard Group Inc. now owns 435,335 shares of the company’s stock valued at $3,909,000 after buying an additional 3,685 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Evelo Biosciences by 1.6% during the second quarter. Northern Trust Corp now owns 139,200 shares of the company’s stock valued at $1,250,000 after buying an additional 2,202 shares in the last quarter. Finally, Morgan Stanley grew its holdings in shares of Evelo Biosciences by 15.0% during the second quarter. Morgan Stanley now owns 64,206 shares of the company’s stock valued at $576,000 after buying an additional 8,366 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

EVLO stock traded down $0.05 during trading on Monday, reaching $4.46. 99,900 shares of the company’s stock were exchanged, compared to its average volume of 46,644. The company has a quick ratio of 10.46, a current ratio of 10.46 and a debt-to-equity ratio of 0.24. Evelo Biosciences has a 1-year low of $4.30 and a 1-year high of $15.89. The company’s fifty day moving average price is $6.18 and its 200-day moving average price is $6.87. The firm has a market cap of $144.71 million, a PE ratio of -1.60 and a beta of -0.32.

Evelo Biosciences (NASDAQ:EVLO) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.67). As a group, sell-side analysts expect that Evelo Biosciences will post -2.55 earnings per share for the current fiscal year.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.

Featured Story: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.